| Line Item | 2025-09-30 | Y/Y |
|---|---|---|
| R&D Expense | $15.4M | +314.6% |
| SG&A Expense | $29.6M | +331.5% |
| Income Tax | $0 | — |
| Net Income | -$40.1M | -294.7% |
| EPS (Basic) | -$1.06 | -171.8% |
| EPS (Diluted) | -$1.06 | -171.8% |
| Line Item | 2025-09-30 | Y/Y |
|---|---|---|
| Cash & Equivalents | $203.3M | +613.0% |
| Accounts Receivable | $250K | — |
| Current Assets | $204.7M | +597.5% |
| Total Assets | $228.7M | +551.5% |
| Current Liabilities | $3.8M | +108.2% |
| Total Liabilities | $6.1M | +74.5% |
| Stockholders' Equity | $222.6M | +604.2% |
| Line Item | 2025-09-30 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$19.6M | -131.8% |
| Capital Expenditures | $8.4M | +397.0% |
| Investing Cash Flow | -$17.5M | -373.6% |
| Financing Cash Flow | $211.9M | +528.4% |
| Free Cash Flow | -$28.1M | -176.2% |